Bertram Lewis
Urology · Zephyrhills, FLNPI 1124096060
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 30.5% of the total. 2025 is the largest year on record at $2,991, 8.2 times the $365 reported in 2019.
Across 158 payments — averaging $55.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$2K
- Teleflex LLC$666
- Coloplast$626
- Astellas Pharma US Inc$430
- Procept Biorobotics Corporation$284
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$2,04023%
- Travel & lodging$1,52917%
- Food & beverage$5,15458%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 16 | $2,693 |
| Boston Scientific | 10 | $1,718 |
| Teleflex LLC | 10 | $666 |
| Coloplast | 12 | $626 |
| Astellas Pharma US Inc | 15 | $430 |
| Procept Biorobotics Corporation | 6 | $284 |
| Johnson & Johnson(3 entities) | 9 | $239 |
| Myriad Genetic Laboratories, Inc. | 6 | $214 |
| Endo Pharmaceuticals Inc. | 9 | $208 |
| Baxter Healthcare | 3 | $188 |
| Endo USA, Inc. | 6 | $182 |
| Axonics, Inc. | 4 | $174 |
| AbbVie(2 entities) | 9 | $161 |
| Laborie Medical Technologies Corp. | 2 | $152 |
| Travere Therapeutics, Inc. | 7 | $137 |
| Sumitomo Pharma America, Inc. | 5 | $118 |
| Merck | 4 | $82 |
| Olympus America Inc. | 1 | $63 |
| Pfizer | 4 | $62 |
| Bayer | 1 | $57 |
| Urovant Sciences Inc | 3 | $55 |
| Neotract Inc. | 2 | $48 |
| 180 Medical, Inc. | 2 | $47 |
| AstraZeneca | 2 | $32 |
| Novartis | 1 | $32 |
| Urogen Pharma, Inc. | 1 | $25 |
| Calyxo, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $24 |
| Coastal Medical Technologies LLC | 1 | $22 |
| Civco Medical Instruments | 1 | $19 |
| Ambu Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $14 |
| ETS Wound Care LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,408
- UroLift$385
- TITAN$188
- ALTIS$182
- TISSEEL$145
- Bulkamid$133
- PreciseTumor$131
- XTANDI$112
- AquaBeam Robotic System$101
How this compares
$8,843 in reported general payments places this provider in the 70th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 98 | $73,871 |
| MyrbetriqMirabegron | 19 | $15,419 |
| Testosterone | 54 | $9,283 |
| Tamsulosin Hcl | 582 | $8,313 |
| Testosterone Cypionate | 111 | $6,474 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 153 | $3,482 |
| Finasteride | 258 | $3,303 |
| Tadalafil | 37 | $1,865 |
| Solifenacin Succinate | 22 | $1,853 |
| Cefdinir | 289 | $1,845 |
| Methenamine Hippurate | 22 | $1,649 |
| Bicalutamide | 30 | $1,463 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,120 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 48 | $656 |
| Doxycycline Hyclate | 71 | $608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $118 | $73,87198 claims |
| Astellas Pharma US IncMyrbetriq | $430 | $15,41919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 urology providers in Florida.
Other urology in Zephyrhills
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
- Raymond PakJacksonville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.